Table 1.
Baseline participant characteristics.
| Total |
Non-abstinence |
Abstinence >1 week |
|
|---|---|---|---|
| N = 192 | n = 119 | n = 73 | |
| Trial, GALA-RIF trial, n (%) | 136 (71) | 96 (81) | 40 (55) |
| Age at inclusion, years | 59 (±9) | 60 (±8) | 58 (±9) |
| Sex, male, n (%) | 161 (84) | 102 (86) | 59 (81) |
| Body mass index, kg/m2 | 29 (±6) | 30 (±6) | 29 (±6) |
| Smoking, n (%) | |||
| Never smoker | 51 (26) | 33 (28) | 18 (25) |
| Previous smoker | 67 (35) | 42 (34) | 25 (34) |
| Current smoker | 68 (35) | 44 (37) | 24 (33) |
| Missing | 6 (3) | 6 (8) | |
| Type 2 diabetes, n (%) | 34 (18) | 21 (18) | 13 (18) |
| Write presence of cardiometabolic risk factors∗, n (%) | 186 (97) | 115 (97) | 71 (97) |
| Alanine transaminase, U/L | 35 (24–56) | 44 (30–69.5) | 27 (20–34) |
| Gamma-glutamyl transferase, U/L | 115 (54.5–291.5) | 185.5 (78.5–358.5) | 63.5 (35.0–131.5) |
| Alkaline phosphatase, U/L | 72.5 (55.5–95.0) | 74.0 (64.0–93.0) | 71.0 (35.5–98.0) |
| Bilirubin, µmol/L | 11 (7–15) | 11 (7–16) | 10 (7–15) |
| Platelets, 109/L | 202 (165–244) | 208 (172–245) | 193 (149–240) |
| INR | 1 (1–1.1) | 1 (1–1.1) | 1 (1–1.1) |
| Albumin, g/L | 43 (41–46) | 43 (41–46) | 44 (41–46) |
| Kleiner fibrosis score, n (%) | |||
| F0 | 7 (3.6) | 5 (4.2) | 2 (2.7) |
| F1 | 37 (19.3) | 22 (18.5) | 15 (20.5) |
| F2 | 67 (34.9) | 47 (39.5) | 20 (27.4) |
| F3 | 38 (19.8) | 28 (23.5) | 10 (13.7) |
| F4 | 39 (20.3) | 15 (12.6) | 24 (32.9) |
| Missing | 4 (2.1) | 2 (1.7) | 2 (1.7) |
| Transient elastography (FibroScan), kPa | 11.4 (7.9–18.4) | 10.2 (8.1–17.3) | 13.2 (7.1–20.5) |
| CAP score, dB/m | 304 (±60.6) | 317 (±59) | 284 (±59) |
| Alcohol | |||
| Alcohol intake for non-abstinent, g/day | 43 (24–69) | ||
| Years of excessive alcohol intake, n (%): | |||
| 1–5 | 19 (9.9) | 9 (7.6) | 10 (13.7) |
| 6–10 | 28 (14.6) | 20 (16.8) | 8 (11.0) |
| 11–20 | 49 (25.5) | 28 (23.5) | 21 (28.8) |
| 21–30 | 40 (20.8) | 27 (22.7) | 13 (17.8) |
| >30 | 47 (24.5) | 32 (26.9) | 15 (20.5) |
| Missing | 9 (4.7) | 3 (2.5) | 6 (8.2) |
| Phosphatidylethanol, μmol/L | 0.5 (0.0–1.3) | 0.9 (0.4–1.8) | 0.0 (0.0–0.1) |
| Carbohydrate-deficient transferrin†, %CDT | 1.9 (1.6–2.3) | 2.1 (1.7–2.6) | 1.7 (1.6–1.9) |
Values are reported as mean ± standard deviation, counts (proportion), and median (IQR).
∗
Cardiometabolic criteria as defined in relation to SLD (2).
†
Only available in GALA-RIF trial. CAP, controlled attenuation parameter; INR, international normalized ratio.